Sacubitril And Valsartan Tablet
Product Images NDC 33342-572

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 33342-572). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

222 (Sacubitril And Valsartan Tablets 24 mg 26 mg 180s)

Label for Sacubitril and Valsartan Tablets, 24 mg/26 mg strength, oral dosage form, packaged with 180 tablets. The label shows storage instructions, manufacturer as Macleods Pharmaceuticals Limited, and that the product is manufactured for Macleods Pharma USA, Inc. Includes barcodes and prescription-only designation.*

FDA Label Image

111 (Sacubitril And Valsartan Tablets 24 mg 26 mg 60s)

Label for Sacubitril and Valsartan Tablets, strength 24 mg/26 mg, oral tablets. Pack contains 60 film-coated tablets. Manufactured by Macleods Pharmaceuticals Limited and Macleods Pharma USA, Inc. The label includes dosage strength, storage instructions, and barcodes.*

FDA Label Image

777 (Sacubitril And Valsartan Tablets 49 mg 51 mg 180s)

Label for Sacubitril and Valsartan Tablets, 49 mg/51 mg strength, oral dosage form. The film-coated tablet package contains 180 tablets. Manufactured by Macleods Pharmaceuticals Limited and Macleods Pharma USA, Inc. Storage instructions and barcode are also shown.*

FDA Label Image

444 (Sacubitril And Valsartan Tablets 49 mg 51 mg 60s)

Label for Sacubitril and Valsartan Tablets, 49 mg/51 mg, oral film-coated tablets. The package contains 60 tablets and is labeled by Macleods Pharmaceuticals Ltd and Macleods Pharma USA, Inc. The label includes usage and storage instructions and highlights the strength of the active ingredients.*

FDA Label Image

897 (Sacubitril And Valsartan Tablets 97 mg 103 mg 180s)

Sacubitril and Valsartan Tablets 97 mg/103 mg film-coated tablets packaging label. The label shows dosage strength, storage instructions (20° to 25°C with excursions), manufacturer Macleods Pharma USA, and a package count of 180 tablets. Barcode and regulatory storage warnings are also visible.*

FDA Label Image

876 (Sacubitril And Valsartan Tablets 97 mg 103 mg 60s)

Label for Sacubitril and Valsartan Tablets 97 mg/103 mg by Macleods Pharmaceuticals Limited. The label shows the active ingredient strengths per film-coated tablet and indicates a package count of 60 tablets. Storage instructions and manufacturer details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. are included on the label.*

FDA Label Image

5252 (Sacubitril Valsartan 4 Figu)

A forest plot chart presenting hazard ratios with 95% confidence intervals comparing sacubitril and valsartan versus enalapril across various subgroups. Subgroups include age, gender, weight, race, region, NYHA class, estimated glomerular filtration rate (GFR), diabetes status, systolic blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, prior hospitalization for heart failure, duration since heart failure diagnosis, cause of heart failure, and presence of ICD devices. The x-axis shows hazard ratios with markers indicating relative efficacy between sacubitril and valsartan and enalapril.*

FDA Label Image

505 (Sacubitril Valsartan 6 Fig)

A forest plot comparing Sacubitril and Valsartan vs. Valsartan across various subgroups including age, gender, race, region, diabetic status, LVEF, atrial fibrillation, NT-proBNP levels, blood pressure, medication use, and kidney function. The plot shows rate ratios with 95% confidence intervals to indicate relative efficacy, with points left of center favoring Sacubitril and Valsartan, and points right favoring Valsartan.*

FDA Label Image

Sacubitril-valsartan-fig-1 (Sacubitril Valsartan Fig 1)

A scatter plot titled 'Effect of Sacubitril and Valsartan on Pharmacokinetics of Coadministered Drugs' showing geometric mean ratios and 90% confidence intervals for AUC and Cmax of various coadministered drugs, including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. The x-axis represents change relative to reference, ranging approximately from 0.5 to 2.*

FDA Label Image

Sacubitril-valsartan-fig-2 (Sacubitril Valsartan Fig 2)

A forest plot chart showing geometric mean ratios and 90% confidence intervals for AUC and Cmax comparing LBQ657 and Valsartan across various populations, including renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate), age groups, sex, and race (Asian/Caucasian, Black/Caucasian). The x-axes display changes relative to reference values for both AUC and Cmax.*

FDA Label Image

333 (Sacubitril Valsartan Fig 3)

Three Kaplan-Meier cumulative failure rate graphs labeled A, B, and C display time to cardiovascular (CV) death and heart failure hospitalizations in the PARADIGM-HF study comparing Sacubitril and Valsartan versus Enalapril over approximately 1,260 days. Each graph shows failure rates on the y-axis and time since randomization (days) on the x-axis, with separate curves for both drugs and numbers at risk listed below.*

FDA Label Image

663 (Sacubitril Valsartan Fig 5)

A line graph titled 'Total Heart Failure Hospitalizations and CV Death in PARAGON-HF' comparing events over time between Valsartan and Sacubitril and Valsartan. The x-axis represents time since randomization in days up to 1440, and the y-axis shows the mean number of events per 100 patients, with Valsartan showing a higher event rate than Sacubitril and Valsartan throughout the period.*

FDA Label Image

366 (Sacubitril Valsartan Fig 7)

This figure shows two hazard ratio plots comparing sacubitril and valsartan to enalapril and valsartan in the PARADIGM-HF and PARAGON-HF studies. The x-axis represents left ventricular ejection fraction at screening (%), and the y-axis shows the hazard ratio with 95% confidence intervals illustrated by dashed lines.*

FDA Label Image

Str (Sacubitril Valsartan Str)

Chemical structure diagram of Sacubitril and Valsartan, showing the molecular connectivity and arrangement of both active ingredients including atoms and bonds, with sodium ions indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.